Anand Mohapatra1, Seth A Strope2, Nick Liu3, Andrew Winer4, Nicole E Benfante5, Jonathan A Coleman5,6, Joel Vetter2, Katie S Murray7. 1. Department of Urology, University of Pittsburgh, Kaufmann Medical Building, 3471 Fifth Ave, Suite 700, Pittsburgh, PA, 15213, USA. amohapatra@wustl.edu. 2. Division of Urologic Surgery, Department of Surgery, Washington University, St. Louis, MO, USA. 3. Department of Urology, St. Joseph Mercy Health System, Ann Arbor, MI, USA. 4. Department of Urology, SUNY Downstate Medical Center, Brooklyn, NY, USA. 5. Department of Surgery-Urology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 6. Department of Urology, Weill Cornell Medical College, New York, NY, USA. 7. Division of Urology, Department of Surgery, University of Missouri, Columbia, MO, USA.
Abstract
PURPOSE: Patients undergoing endoscopic management for upper tract urothelial carcinoma often progress to definitive therapy with radical nephroureterectomy. This study examined the rate of progression as well as risk factors for transitions in treatment over time. METHODS: Retrospective review at two institutions identified patients undergoing endoscopic management for upper tract urothelial carcinoma. Patients were assessed for progression to radical nephroureterectomy. Baseline characteristics were compared using Chi square analysis. Kaplan-Meier method analyzed the probability of patients not progressing to radical nephroureterectomy. Cox proportional hazards identified factors associated with progression to radical nephroureterectomy. RESULTS: Eighty-one patients had endoscopic management alone and 89 progressed to radical nephroureterectomy. The two groups had similar age, histories of bladder cancer, and Charlson comorbidity index. Positive urinary cytology, ureteroscopic visualization, and biopsy grade were higher in those progressing to RNU (p < 0.001). Hazard modeling demonstrated higher rates of progression to radical nephroureterectomy with positive biopsy (HR 11.8, 95% CI 2.4-59.5, p = 0.003) or visible lesion on ureteroscopy (HR 8.4, 95% CI 3.0-23.9, p < 0.001). Patients with a higher Charlson comorbidity index were less likely to have radical nephroureterectomy. On Kaplan-Meier modeling, the probability of not undergoing radical nephroureterectomy at 2 years and 5 years was 50% and 20%, respectively. CONCLUSIONS: Patients who progress to radical nephroureterectomy after endoscopic management have fewer comorbid conditions and changes in disease status including visible lesions on ureteroscopy and positive biopsies. The high rate of progression to radical nephroureterectomy reinforces the need for long-term follow-up of these patients.
PURPOSE:Patients undergoing endoscopic management for upper tract urothelial carcinoma often progress to definitive therapy with radical nephroureterectomy. This study examined the rate of progression as well as risk factors for transitions in treatment over time. METHODS: Retrospective review at two institutions identified patients undergoing endoscopic management for upper tract urothelial carcinoma. Patients were assessed for progression to radical nephroureterectomy. Baseline characteristics were compared using Chi square analysis. Kaplan-Meier method analyzed the probability of patients not progressing to radical nephroureterectomy. Cox proportional hazards identified factors associated with progression to radical nephroureterectomy. RESULTS: Eighty-one patients had endoscopic management alone and 89 progressed to radical nephroureterectomy. The two groups had similar age, histories of bladder cancer, and Charlson comorbidity index. Positive urinary cytology, ureteroscopic visualization, and biopsy grade were higher in those progressing to RNU (p < 0.001). Hazard modeling demonstrated higher rates of progression to radical nephroureterectomy with positive biopsy (HR 11.8, 95% CI 2.4-59.5, p = 0.003) or visible lesion on ureteroscopy (HR 8.4, 95% CI 3.0-23.9, p < 0.001). Patients with a higher Charlson comorbidity index were less likely to have radical nephroureterectomy. On Kaplan-Meier modeling, the probability of not undergoing radical nephroureterectomy at 2 years and 5 years was 50% and 20%, respectively. CONCLUSIONS:Patients who progress to radical nephroureterectomy after endoscopic management have fewer comorbid conditions and changes in disease status including visible lesions on ureteroscopy and positive biopsies. The high rate of progression to radical nephroureterectomy reinforces the need for long-term follow-up of these patients.
Authors: Robert Abouassaly; Shabbir M H Alibhai; Nasir Shah; Narhari Timilshina; Neil Fleshner; Antonio Finelli Journal: Urology Date: 2010-06-19 Impact factor: 2.649
Authors: William C Huang; Andrew S Levey; Angel M Serio; Mark Snyder; Andrew J Vickers; Ganesh V Raj; Peter T Scardino; Paul Russo Journal: Lancet Oncol Date: 2006-09 Impact factor: 41.316
Authors: Mark L Cutress; Grant D Stewart; Paimaun Zakikhani; Simon Phipps; Ben G Thomas; David A Tolley Journal: BJU Int Date: 2012-04-03 Impact factor: 5.588
Authors: Thomas Seisen; Benoit Peyronnet; Jose Luis Dominguez-Escrig; Harman M Bruins; Cathy Yuhong Yuan; Marko Babjuk; Andreas Böhle; Maximilian Burger; Eva M Compérat; Nigel C Cowan; Eero Kaasinen; Joan Palou; Bas W G van Rhijn; Richard J Sylvester; Richard Zigeuner; Shahrokh F Shariat; Morgan Rouprêt Journal: Eur Urol Date: 2016-07-28 Impact factor: 20.096
Authors: R Yakoubi; P Colin; T Seisen; P Léon; L Nison; G Bozzini; S F Shariat; M Rouprêt Journal: Eur J Surg Oncol Date: 2014-07-25 Impact factor: 4.424
Authors: Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood Journal: Cancer Date: 2009-03-15 Impact factor: 6.860
Authors: Jeremy Ng Chieng Hin; Dinul Hettiarachchilage; Paul Gravestock; Bhavan Rai; Bhaskar K Somani; Rajan Veeratterapillay Journal: Curr Urol Rep Date: 2021-10-07 Impact factor: 3.092